Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations (vol 110, pg 894, 2014)

被引：2
|
作者：
Hu, S.
Mathijssen, R. H. J.
de Bruijn, P.
Baker, S. D.
Sparreboom, A.
机构：
来源：
BRITISH JOURNAL OF CANCER | 2017年 / 117卷 / 05期
关键词：
D O I：
10.1038/bjc.2017.217
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Correction to: British Journal of Cancer (2014) 110, 894–898. doi:10.1038/bjc.2013.811; published online 7 January 2014 After publication of the above paper in the British Journal of Cancer, a discrepancy was found in the text. The Results section contains the following: ‘As a representative of thisclass of TKIs, sorafenib was further evaluated and found to also potently inhibit the OATP1B1-mediated transport of docetaxel with a half-inhibitory maximum concentration of 6.
引用
收藏
页码：e3 / e3
页数：1
相关论文
共 50 条
  • [1] Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations
    Hu, S.
    Mathijssen, R. H. J.
    de Bruijn, P.
    Baker, S. D.
    Sparreboom, A.
    BRITISH JOURNAL OF CANCER, 2014, 110 (04) : 894 - 898
  • [2] Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations
    Hu, Shuiying
    Bruijn, Peter D.
    Mathijssen, Ron H. J.
    Baker, Sharyn D.
    Sparreboom, Alex
    CANCER RESEARCH, 2014, 74 (19)
  • [3] Erratum: Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations
    S Hu
    R H J Mathijssen
    P de Bruijn
    S D Baker
    A Sparreboom
    British Journal of Cancer, 2017, 117 : e3 - e3
  • [4] Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro–in vivo correlations
    S Hu
    R H J Mathijssen
    P de Bruijn
    S D Baker
    A Sparreboom
    British Journal of Cancer, 2014, 110 : 894 - 898
  • [5] Phosphorylation and function of OATP1B1 with tyrosine kinase inhibitors
    Hayden, Elizabeth
    FASEB JOURNAL, 2020, 34
  • [6] INHIBITION OF OATP1B1 BY GLUCURONIDES: DOES IN VITRO TRANSLATE TO IN VIVO RELEVANCE?
    Sulivan, Rebecca A.
    Galetin, Aleksandra
    Sharma, Pradeep
    Rollison, Helen
    Fenner, Katherine
    DRUG METABOLISM REVIEWS, 2015, 47 : 117 - 117
  • [7] Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors
    Garrison, Dominique A.
    Talebi, Zahra
    Eisenmann, Eric D.
    Sparreboom, Alex
    Baker, Sharyn D.
    PHARMACEUTICS, 2020, 12 (09) : 1 - 18
  • [8] Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen
    Drabison, Thomas
    Boeckman, Mike
    Yang, Yan
    Huang, Kevin M.
    de Bruijn, Peter
    Nepal, Mahesh R.
    Silvaroli, Josie A.
    Chowdhury, Anika T.
    Eisenmann, Eric D.
    Cheng, Xiaolin
    Pabla, Navjotsingh
    Mathijssen, Ron H. J.
    Baker, Sharyn D.
    Hu, Shuiying
    Sparreboom, Alex
    Talebi, Zahra
    CANCER RESEARCH COMMUNICATIONS, 2024, 4 (09): : 2489 - 2497
  • [9] Modulation of OATP1B1 function by LYN-kinase inhibitors
    Hu, S.
    Chen, M.
    Gibson, A.
    Sparreboom, A.
    Sprowl, J.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E43 - E43
  • [10] In Silico and in Vitro Assessment of OATP1B1 Inhibition in Drug Discovery
    Danielson, Matthew L.
    Sawada, Geri A.
    Raub, Thomas J.
    Desai, Prashant V.
    MOLECULAR PHARMACEUTICS, 2018, 15 (08) : 3060 - 3068
12345